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European Stroke Prevention Study ESPS 2,
Clopidogrel vs Aspirin for Prevention of Recurrent Ischemic
Events-CAPRIE AND Management of ATherothrombosis
with Clopidogrel in High-risk patients-MATCH.
Why are these studies of clinical importance? 
Before these trials it was already known that
antiplatelets like aspirin and ticlopidine reduce the incidence of
a composite outcome of ischaemic stroke, MI or vascular death.
However, both these drugs have serious potential side effects,
like GI bleeding, bone marrow suppression, rash and diarrhoea. 
ESPS 1 came out in 1987. In this trial dipyridamole 75
mg tid was given with ASA 330 mg tid for two years in
people with previous ischaemic stroke or TIA. The
combination showed a striking 38% reduction in secondary
stroke over the group treated with placebo. Prior to this two
other studies had failed to show superiority of this
combination. ESPS 2 was then undertaken in 1996 to answer
clearly the efficacy of ASA and Dipyridamole alone in
secondary prevention of ischaemic strokes and to see whether
the combination had any real advantage.
Clopidogrel was a new agent which had shown benefit
in animal studies. It inhibits platelet aggregation by inhibiting
binding of ADP to its receptor (GpIIb-IIIa) on platelets and
thereby blocking platelet activation.
CAPRIE was a randomized clinical trial with a head to
head comparison of aspirin and clopidogrel in patients with
history of ischaemic stroke, myocardial infarction or peripheral
vascular disease. The outcome was a composite of ischaemic
stroke, MI or vascular death.
MATCH on the other hand was a study undertaken
once the results of CAPRIE were out and had shown some
advantage of clopidogrel over aspirin. The purpose of this
study was to evaluate whether aspirin added to clopidogrel
would reduce the risk of recurrent ischaemic vascular events in
high risk patients with TIA or stroke.
Who were the participants?
In ESPS 2, 6602 patients were recruited from 13
European countries. Patients were eligible if they were more
than 18 years old and had experienced a TIA or a completed
ischaemic stroke within the preceding three months.
Randomization was done centrally by a computerized system.
In CAPRIE 19,185 patients from 384 clinical centers in
sixteen countries were randomized. Most of these were again
European countries, and no Asian contribution was there. All
participants had to have either a history of acute ischaemic
stroke (1 week to 6 months before randomization), or history
of MI (<35 days before randomization) or atherosclerotic
peripheral arterial disease. Computer generated randomization
was done by the Independent Statistical Center and the
treatment allocation was double blinded.
MATCH included 7599 patients from 507 centers in 28
countries. Again most were European nations, except some
contribution from Singapore, Taiwan and Hong Kong. People
with ischaemic stroke or TIA in the previous 3 months plus one
or more of the following; previous ischaemic stroke, previous
MI, angina pectoris, DM, or symptomatic PAD in the past 3
years were included. Treatment allocation was done centrally
by a computer generated list.
What was the intervention?
In ESPS 2, four treatment groups were assigned
randomly- ASA 25 mg bid, modified release dipyridamole
200mg bid, ASA 25 mg bid plus dipyridamole 200 mg bid and
matched placebo. Each patient was followed up for two years
regardless of compliance with study medication or occurrence
of a non fatal end point. Follow-up was done at one month after
randomization, and then at three month intervals throughout.
In CAPRIE patients received blister packs containing
either 75 mg tablets of clopidogrel plus aspirin placebo or 325
mg tablets of aspirin plus clopidogrel placebo. Patients were
asked to take one of each tablet daily with their morning meal.
Follow-up visits took place monthly for the first 4 months and
every 4 months thereafter. At these visits, information was
collected on adverse events and use of study drug and
concomitant medications, and blood was taken for
hematological and biochemical assessments by one of three
central laboratories.
In MATCH patients were randomly allocated either
aspirin 75 mg once daily or matching placebo tablet;
furthermore, all patients received clopidogrel 75 mg once daily.
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Study treatment was started on the day of randomization and
continued for 18 months. After the randomization visit, follow-
up visits were scheduled at 1, 3, 6, 12, and 18 months. These
visits were supplemented by monthly follow-up telephone calls
to the patient.
What was the outcome?
ESPS2: There was a significant difference for ASA and
for Dipyridamole for reducing the risk of recurrent stroke
(p<0.001 for both) and stroke or death (p=0.003 and p=0.002).
Stroke risk was significantly reduced by 18.1% with ASA
alone, by 16.3% with DP alone and by 37% by the
combination. With the combination therapy there was a
significant 23.1% risk reduction in stroke risk over ASA alone
and a significant 24.7% over DP alone.
CAPRIE: For a composite outcome of ischaemic
stroke, MI or vascular death, there were 939 events in the
clopidogrel arm and 1021 events in the aspirin arm. This
translated to a relative risk reduction of 8.7% and reached a
statistical significance at p=0.043. For patients with stoke and
MI, the relative risk reduction in composite outcome was 7.3%
and 3.7% respectively, although both these were not
significant. For peripheral arterial disease patients however, the
relative risk reduction was 23.8% in favour of clopidogrel
(p=0.0028).The frequency of severe rash and diarrhoea was
higher with clopidogrel. More frequent with aspirin were
severe upper GI discomfort, ICH, and GI haemorrhage.
MATCH: The primary endpoint was the first
occurrence of an event in the composite of ischaemic stroke,
myocardial infarction, vascular or rehospitalisation for an
acute ischaemic event. The relative risk reduction in favour of
clopidogrel in the intention-to-treat population was 6·4% and
was in the range that was reported in the CAPRIE trial (8·7%).
Even though there were fewer events in the aspirin plus
clopidogrel arm, compared to clopidogrel alone, the
combination resulted in a significantly higher bleeding rate
that offset any beneficial effect. However, no significant
increase in fatal bleeding was recorded and mortality was the
same in both groups.
What were the conclusions?
ESPS 2 concluded that DP modified release
formulation, 200 mg bid is effective in the secondary
prevention of stroke and TIA when compared to placebo and
that the combination of ASA and DP provides a truly additive
benefit with an odds reduction of 43.7%. DP was associated
with headache and GI disorders, particularly diarrhoea,
generally early in the trial. AS A containing regimens had
significantly more bleeding complications even at low dose but
the combination was no worse than ASA alone.
CAPRIE concluded that clopidogrel provides an
additional 8.7% relative risk reduction over and above the 25%
reduction expected to be provided by aspirin. However, it was
not powered to detect the risk reduction of particular events
like ischaemic stroke or MI. The benefits of clopidogrel were
truly much more in patients with peripheral arterial disease.
MATCH concluded that because of a significantly large
number of bleeding events, and no significant reduction in the
recurrent events, there was no additional clinical value of
adding aspirin to clopidogrel in high risk patients with ischemic
stroke or TIA.
How does this impact us?
It appears that for a patient with stroke requiring
secondary prevention Aspirin alone, Clopidogrel alone, or
Aspirin combined with slow release Dipyridamole are all
acceptable first options. However, these decisions must be
made with careful considerations to finance (these are lifelong
drugs), individual susceptibilities and reaction to any
component of drug combination.
Dipyridamole combined with Aspirin is somewhat
advantageous over either drug alone for secondary prevention
of non fatal stroke and TIA. However it does not have any
evidence of impact on composite vascular outcomes including
vascular death. There is no evidence that dipyridamole alone is
more efficacious than aspirin. It must also be assured that the
combination does not pose risk to patient - e.g. exacerbation of
tachycardia or coronary ischaemia by Dipyridamole .The
combination however, does not carry additional risk of
haemorrhage as for Clopidogrel and ASA.
Clopidogrel is a relatively expensive medication for
a poor nation like ours. The evidence for benefit in patients
with one particular disease group like ischaemic stroke or
MI is not robust, and therefore it is probably advisable to
stick to good old aspirin unless a composite risk has to be
addressed. The combination of aspirin and clopidogrel is
not advisable as its benefit is not proven and the risk of
bleeding is quite significant.
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